TD Management Options
Pharmacologic Management Options for Patients With Tardive Dyskinesia

Released: October 17, 2022

Expiration: October 16, 2023

Diana O. Perkins
Diana O. Perkins, MD, MPH
Rajiv Tandon
Rajiv Tandon, MD

Activity

Progress
1
Course Completed
In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.